Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

Novo sells semaglutide as Ozempic, Rybelsus and Wegovy. The CMS will treat the different forms as a single product in price ...

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS ...

Semaglutide (Ozempic) is 1 of 15 medications that will be included in yearly price negotiations between Medicare and ...

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

Announcement of the 15 medicines chosen for the second round of negotiations was one of the Biden administration’s final ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.